Isabella Guzzo1, Federica Morolli2, Francesca Diomedi Camassei3, Antonina Piazza4, Elvira Poggi4, Luca Dello Strologo2. 1. Nephrology Unit, Department of Pediatrics, Institute for Scientific Research, Bambino Gesù Children's Hospital, Piazza S. Onofrio 4, 00165, Rome, Italy. isabella.guzzo@opbg.net. 2. Nephrology Unit, Department of Pediatrics, Institute for Scientific Research, Bambino Gesù Children's Hospital, Piazza S. Onofrio 4, 00165, Rome, Italy. 3. Pathology Unit, Department of Laboratories, Institute for Scientific Research, Bambino Gesù Children's Hospital, Piazza S. Onofrio 4, 00165, Rome, Italy. 4. National Council of Researches, IFT Unit of Rome S. Camillo Hospital - Regional Transplant Center Lazio, S. Camillo Hospital, C.ne Gianicolense 87, 00152, Rome, Italy.
Abstract
BACKGROUND: Several cases of severe antibody-mediated rejection (AMR) secondary to antibodies against the angiotensin II type 1 receptor (AT1R-Ab) have been described with variable outcome. CASE-DIAGNOSIS/TREATMENT: We report the case of a 13-year-old boy whose first kidney transplant failed due to steroid-resistant acute cellular rejection, with the subsequent development of sensitization. He received a second kidney transplant which was complicated by early humoral rejection, with weakly positive staining for the complement degradation product C4d. Test results were negative for donor-specific antibodies against human leukocyte antigens (HLA-DSA) and MHC class I-related chain A (MICA) but positive for AT1R-Ab. Retrospective testing of the sera collected during the first kidney transplant was also positive for AT1R-Ab. We therefore hypothesized that the failure of the first transplant was secondary to the same cause. Losartan was immediately introduced into the therapeutic regimen, and the patient showed an excellent clinical and histological recovery. CONCLUSIONS: Testing for AT1R-Ab in any hypertensive patient with acute rejection who tests negative or weakly positive for C4d and negative for HLA-DSA and who is refractory to therapy is highly advisable. Pre-transplant AT1R-Ab may be indicative of the outcome in patients whose first transplant failed. Prompt initiation of treatment with losartan-immediately after transplantation in patients with pre-existing AT1R-Ab-should be encouraged.
BACKGROUND: Several cases of severe antibody-mediated rejection (AMR) secondary to antibodies against the angiotensin II type 1 receptor (AT1R-Ab) have been described with variable outcome. CASE-DIAGNOSIS/TREATMENT: We report the case of a 13-year-old boy whose first kidney transplant failed due to steroid-resistant acute cellular rejection, with the subsequent development of sensitization. He received a second kidney transplant which was complicated by early humoral rejection, with weakly positive staining for the complement degradation product C4d. Test results were negative for donor-specific antibodies against human leukocyte antigens (HLA-DSA) and MHC class I-related chain A (MICA) but positive for AT1R-Ab. Retrospective testing of the sera collected during the first kidney transplant was also positive for AT1R-Ab. We therefore hypothesized that the failure of the first transplant was secondary to the same cause. Losartan was immediately introduced into the therapeutic regimen, and the patient showed an excellent clinical and histological recovery. CONCLUSIONS: Testing for AT1R-Ab in any hypertensivepatient with acute rejection who tests negative or weakly positive for C4d and negative for HLA-DSA and who is refractory to therapy is highly advisable. Pre-transplant AT1R-Ab may be indicative of the outcome in patients whose first transplant failed. Prompt initiation of treatment with losartan-immediately after transplantation in patients with pre-existing AT1R-Ab-should be encouraged.
Authors: Alexander Fuss; Christopher M Hope; Susan Deayton; Greg Donald Bennett; Rhonda Holdsworth; Robert P Carroll; P Toby H Coates Journal: Nephrology (Carlton) Date: 2015-07 Impact factor: 2.506
Authors: Nancy L Reinsmoen; Chih-Hung Lai; Harald Heidecke; Mark Haas; Kai Cao; Geraldine Ong; Mehrnoush Naim; Qi Wang; James Mirocha; Joseph Kahwaji; Ashley A Vo; Stanley C Jordan; Duska Dragun Journal: Transplantation Date: 2010-12-27 Impact factor: 4.939
Authors: Philip F Halloran; Jessica Chang; Konrad Famulski; Luis G Hidalgo; Israel D R Salazar; Maribel Merino Lopez; Arthur Matas; Michael Picton; Declan de Freitas; Jonathan Bromberg; Daniel Serón; Joana Sellarés; Gunilla Einecke; Jeff Reeve Journal: J Am Soc Nephrol Date: 2014-11-06 Impact factor: 10.121
Authors: Anjelo Jobert; Nitesh Rao; Sue Deayton; Greg D Bennett; John Brealey; James Nolan; Robert P Carroll; Duska Dragun; Patrick T Coates Journal: Nephrology (Carlton) Date: 2015-03 Impact factor: 2.506
Authors: M Taniguchi; L M Rebellato; J Cai; J Hopfield; K P Briley; C E Haisch; P G Catrou; P Bolin; K Parker; W T Kendrick; S A Kendrick; R C Harland; P I Terasaki Journal: Am J Transplant Date: 2013-08-13 Impact factor: 8.086
Authors: Meghan H Pearl; Qiuheng Zhang; Miguel Fernando Palma Diaz; Jonathan Grotts; Maura Rossetti; David Elashoff; David W Gjertson; Patricia Weng; Elaine F Reed; Eileen Tsai Chambers Journal: Kidney Int Date: 2017-09-18 Impact factor: 10.612